BioLife Solutions, Inc. (NASDAQ:BLFS) CRO Marcus Schulz sold 650 shares of the firm’s stock in a transaction dated Tuesday, April 20th. The stock was sold at an average price of $32.10, for a total value of $20,865.00. Following the completion of the transaction, the executive now directly owns 39,145 shares in the company, valued at $1,256,554.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Marcus Schulz also recently made the following trade(s):
- On Thursday, April 8th, Marcus Schulz sold 224 shares of BioLife Solutions stock. The stock was sold at an average price of $35.77, for a total value of $8,012.48.
NASDAQ BLFS opened at $32.92 on Friday. The company has a market cap of $1.10 billion, a P/E ratio of -45.10, a P/E/G ratio of 50.41 and a beta of 1.55. The business’s 50 day moving average price is $36.20 and its 200-day moving average price is $36.85. BioLife Solutions, Inc. has a fifty-two week low of $10.00 and a fifty-two week high of $47.97.
BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Sunday, March 21st. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.04). The company had revenue of $14.73 million for the quarter, compared to the consensus estimate of $13.43 million. BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. On average, research analysts expect that BioLife Solutions, Inc. will post 0.01 EPS for the current fiscal year.
A number of research analysts have recently weighed in on BLFS shares. Zacks Investment Research raised BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, January 6th. Stephens lifted their price objective on BioLife Solutions from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, March 23rd. KeyCorp boosted their price target on BioLife Solutions from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 29th. Northland Securities boosted their price target on BioLife Solutions from $35.00 to $55.00 in a report on Monday, December 28th. Finally, Benchmark raised BioLife Solutions from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Monday, March 29th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. BioLife Solutions has an average rating of “Buy” and a consensus target price of $45.10.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower House Partners LLP bought a new position in BioLife Solutions in the 4th quarter valued at $18,872,000. Jennison Associates LLC bought a new position in BioLife Solutions in the 4th quarter valued at $17,934,000. FMR LLC bought a new position in BioLife Solutions in the 1st quarter valued at $2,684,000. Pier Capital LLC bought a new position in BioLife Solutions in the 4th quarter valued at $5,907,000. Finally, BlackRock Inc. grew its position in BioLife Solutions by 10.9% in the 4th quarter. BlackRock Inc. now owns 1,232,671 shares of the medical equipment provider’s stock valued at $49,172,000 after acquiring an additional 121,334 shares during the last quarter. 67.66% of the stock is currently owned by hedge funds and other institutional investors.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also: Net Income
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.